Paper36918226
CD47 expression is critical for CAR T-cell survival in vivo.
Beckett AN and 8 others. J Immunother Cancer, 2023. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. CD47 expression is critical for CAR T-cell survival in vivo. Papers, record 36918226. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36918226
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Humans | |
| Immunotherapy, Adoptive | |
| CD47 Antigen | |
| Leukocytes, Mononuclear | |
| Cell Survival | |
| Cell Line, Tumor |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA096832 | NCI NIH HHS | United States | P01CA096832 | PubMed and NIH | NIH RePORTER |
| P30 CA021765 | NCI NIH HHS | United States | P30CA021765 | PubMed and NIH | NIH RePORTER |
| R50 CA211481 | NCI NIH HHS | United States | R50CA211481 | PubMed and NIH | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29065481 | CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/29065481 | PubMed |
| 2 | 30380386 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380386 | PubMed |
| 3 | 33148882 | MyD88/CD40 signaling retains CAR T cells in a less differentiated state. | JCI Insight | 2020 | https://conductscience.org/library/papers/33148882 | PubMed |
| 4 | 24006483 | CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions. | Mol Biol Cell | 2013 | https://conductscience.org/library/papers/24006483 | PubMed |
| 5 | 33614914 | Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/33614914 | PubMed |
| 6 | 11156950 | Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow. | FASEB J | 2001 | https://conductscience.org/library/papers/11156950 | PubMed |
| 7 | 32019780 | Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/32019780 | PubMed |
| 8 | 32421049 | Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure-function. | Antib Ther | 2020 | https://conductscience.org/library/papers/32421049 | PubMed |
| 9 | 15699129 | Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. | J Immunol | 2005 | https://conductscience.org/library/papers/15699129 | PubMed |
| 10 | 10358145 | CD47 signals T cell death. | J Immunol | 1999 | https://conductscience.org/library/papers/10358145 | PubMed |
| 11 | 17299405 | Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. | Mol Ther | 2007 | https://conductscience.org/library/papers/17299405 | PubMed |
| 12 | 29552579 | Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma. | Mol Ther Methods Clin Dev | 2018 | https://conductscience.org/library/papers/29552579 | PubMed |
| 13 | 32728609 | Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells. | Mol Ther Oncolytics | 2020 | https://conductscience.org/library/papers/32728609 | PubMed |
| 14 | 11514609 | CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. | J Exp Med | 2001 | https://conductscience.org/library/papers/11514609 | PubMed |
| 15 | 28807568 | Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. | Mol Ther | 2017 | https://conductscience.org/library/papers/28807568 | PubMed |
| 16 | 23722425 | Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. | Science | 2013 | https://conductscience.org/library/papers/23722425 | PubMed |
| 17 | 10856220 | Role of CD47 as a marker of self on red blood cells. | Science | 2000 | https://conductscience.org/library/papers/10856220 | PubMed |
| 18 | 9548474 | T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4. | J Immunol | 1997 | https://conductscience.org/library/papers/9548474 | PubMed |
| 19 | 34257155 | Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34257155 | PubMed |
| 20 | 31462760 | Phagocytosis checkpoints as new targets for cancer immunotherapy. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/31462760 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42643739 | Therapeutic biologics interference in serological and pre-transfusion testing. | Front Immunol | 2026 | https://conductscience.org/library/papers/42643739 | PubMed |
| 42607363 | Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma. | Biomed Pharmacother | 2026 | https://conductscience.org/library/papers/42607363 | PubMed |
| 42500710 | Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies. | Smart Mol | 2026 | https://conductscience.org/library/papers/42500710 | PubMed |
| 42004948 | Erythrocyte membrane-liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells. | Front Immunol | 2026 | https://conductscience.org/library/papers/42004948 | PubMed |
| 41627173 | LRRC15-CAR T Cells for the Treatment of Osteosarcoma. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41627173 | PubMed |
| 41511303 | CAR-NK Engineering to Overcome TME Barriers. | Cells | 2025 | https://conductscience.org/library/papers/41511303 | PubMed |
| 41485186 | Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41485186 | PubMed |
| 41428241 | CD47 signaling in aging and age-related diseases: mechanisms, challenges, and therapeutic opportunities. | Biogerontology | 2025 | https://conductscience.org/library/papers/41428241 | PubMed |
| 41419929 | Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41419929 | PubMed |
| 41354926 | Improving CAR T cell therapy against malignancies through gene knock-down/out strategies: a systematic review. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41354926 | PubMed |
| 41276863 | Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors. | Inflamm Regen | 2025 | https://conductscience.org/library/papers/41276863 | PubMed |
| 41249483 | Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer. | Nat Immunol | 2025 | https://conductscience.org/library/papers/41249483 | PubMed |
| 41084874 | Allogeneic CAR-T cell therapy in autoimmune diseases. | Immunotherapy | 2025 | https://conductscience.org/library/papers/41084874 | PubMed |
| 41019041 | Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway. | Front Immunol | 2025 | https://conductscience.org/library/papers/41019041 | PubMed |
| 40005909 | Mesenchymal Stem Cells with Simultaneous Overexpression of GPX3 and CD47 for the Treatment of Drug-Induced Acute Liver Injury. | Vet Sci | 2025 | https://conductscience.org/library/papers/40005909 | PubMed |
| 39906740 | A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells. | Front Immunol | 2024 | https://conductscience.org/library/papers/39906740 | PubMed |
| 39624236 | Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39624236 | PubMed |
| 39584189 | Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells. | Clin Transl Immunology | 2024 | https://conductscience.org/library/papers/39584189 | PubMed |
| 39521782 | Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker. | Nat Commun | 2024 | https://conductscience.org/library/papers/39521782 | PubMed |
| 39382819 | Developing CAR T-Cell Therapies for Pediatric Solid Tumors. | Paediatr Drugs | 2025 | https://conductscience.org/library/papers/39382819 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36918226
GET https://conductscience.org/api/papers/v1/36918226/references?page=2